Saphenous graft atherosclerosis as assessed by optical coherence tomography data for stenotic and non-stenotic lesions from the OCTOPUS registry

Kubiak, Grzegorz; Pociask, Elżbieta; Wańha, Wojciech; Dobrolińska, Magdalena; Gąsior, Paweł; Smołka, Grzegorz; Ochała, Andrzej; Gąsior, Zbigniew; Wojakowski, Wojciech; Roleder, Tomasz

doi:10.5114/aic.2018.76407

Cited by 3 publications

(3 citation statements)

References 30 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that BVS characterized stable scaffold concentricity up to 48 months after the implantation. It may be explained by the fact that vein graft lesions are less calcified and thus an appropriate scaffold shape was much more easily achieved as compared to native coronary arteries [22, 23]. Additionally, the stable BVS shape may explain the lack of malapposition during the follow-up, which in line with the animal model observations [24], but in contrast to human studies.…”

Section: Discussionmentioning

confidence: 87%

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

Roleder

Pociask

Wańha

et al. 2019

pwki

Self Cite

View full text Add to dashboard Cite

Introduction: There are no data presenting a serial assessment of vein graft healing after bioresorbable vascular scaffold (BVS) implantation at long-term follow-up. Aim: To describe ABSORB BVS healing in vein grafts by optical coherence tomography (OCT) and high-definition intravascular imaging (HD-IVUS) at long-term follow-up. Material and methods: The study group consisted of 6 patients. The first patient had serial OCT assessment of BVS implanted in the saphenous vein grafts (SVG) at baseline and at 3-, 6-, 18-month follow-up and the second patient had OCT assessment of BVS implanted in the SVG at baseline and 24-, 48-month follow-up. The second and the third patients had OCT and HD-IVUS imaging at baseline and 48-month follow-up. The last 3 patients had OCT imaging of BVS implanted in the native coronary artery at 48-month follow-up. Results: There were no differences in neointimal hyperplasia after BVS implantation between each time point. However, complete scaffold coverage was observed only 48 months after implantation. Out of 202 analyzed scaffold struts, there were 67 (33%) black boxes detectable at 48-month follow-up. HD-IVUS presented plaque burden up to 67% at the segment of BVS implantation at 48-months follow-up. There was a difference in neointimal hyperplasia thickness (1.27 (0.953-1.696) vs. 0.757 (0.633-0.848), p < 0.001) between a native coronary artery and BVS scaffolds at 48-month follow-up. Conclusions: Bioresorbable vascular scaffold implanted in SVG characterized moderate neointimal hyperplasia as excessive as compared to native coronary arteries at long-term follow-up. The complete scaffold coverage was observed only 48 months after implantation.

show abstract

Section: Discussionmentioning

confidence: 87%

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

Roleder

Pociask

Wańha

et al. 2019

pwki

Self Cite

View full text Add to dashboard Cite

show abstract

“…Each parameter was associated with increased atherosclerosis and cardiovascular risk [19][20][21]. Kubiak et al [22] investigated atherosclerosis of saphenous grafts with optical coherence tomography and found that decreased ejection fraction and renal insufficiency were associated with increased atherosclerosis in saphenous grafts. Their finding was similar to the findings of our study, where GF was significantly associated with HFrEF and increased creatinine level.…”

Section: Discussionmentioning

confidence: 99%

The CHA2DS2-VASc Score as an Early Predictor of Graft Failure After Coronary Artery Bypass Surgery

Taşbulak¹,

Şahin²

2022

Cureus

View full text Add to dashboard Cite

Background and objectiveGraft patency is one of the major concerns after coronary artery bypass graft (CABG) surgery. The CHA 2 DS 2 -VASc [congestive heart failure, hypertension, age ≥75 years, diabetes mellitus (DM), stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category] score is a tool that was developed to predict the risk of thrombotic events in patients with atrial fibrillation (AF). In this study, we evaluated the use of the CHA 2 DS 2 -VASc score as a simple tool for predicting graft failure (GF) among patients who underwent CABG surgery. MethodsIn this retrospective case-control study, a total of 280 patients were enrolled after applying the exclusion criteria. Angiograms were analyzed by using the QCA software system (Pie Medical Imaging, Maastricht, The Netherlands) for each patient. A graft was described as failed if it had 70% or more stenosis or was completely occluded. Patients were classified into two groups: group one included patients without GF (GF-N) and group two included patients with GF (GF-Y). Thereafter, the CHA 2 DS 2 -VASc risk score was calculated for each patient. ResultsIn our cohort, 136 patients had GF (GF-Y group) and 144 patients did not have GF (GF-N group). GF-N and GF-Y patients had their angiography performed 100.31 ± 8.04 and 103.49 ± 8.41 months after CABG, respectively. GF-Y group had a significantly higher rate of DM, hypertension, and heart failure with reduced ejection fraction (HFrEF). GF-Y group had higher CHA 2 DS 2 (GF-N group: 1.47 ± 0.91 vs. GF-Y group: 2.57 ± 1.17, p=0.0001) and CHA 2 DS 2 -VASc score (GF-N group: 2.80 ± 1.11 vs. GF-Y group: 4.15 ± 1.25, p=0.0001).Analyses showed that only CHA 2 DS 2 -VASc was an independent predictor of GF while other parameters including DM, hypertension, HFrEF, creatinine, and CHADS 2 were not found to be independent predictors of GF. A CHA 2 DS 2 -VASc score of >3 predicted GF with a sensitivity of 65.44% and a specificity of 74.31%. ConclusionsThe CHA 2 DS 2 -VASc score might be used as a feasible and simple method to predict the risk of GF after CABG surgery.

show abstract

“…Saphenous vein graft (SVG) failure affects 15-35% of patients within five years and 29-68% of patients ten years after the procedure [1,2]. Vein graft stenosis is characterized by an accelerated and different progression of atherosclerosis as compared with the process occurring in native coronary arteries [3]. Plaque morphology in SVG consist of friable tissue prone to cause distal embolization during percutaneous coronary intervention (PCI) [4,5].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis—Multicenter SVG PCI PROTECTA Study

Wańha

Mielczarek

Gilis‐Malinowska

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background: Evidence concerning the efficacy of the embolic protection devices (EPDs) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI) is sparse. The study was designed to compare major cardiovascular events of all-comer population of SVG PCI with and without EPDs at one year of follow-up. Methods and results: A multi-center registry comparing PCI with and without EPDs in consecutive patients undergoing PCI of SVG. The group comprised 792 patients, among which 266 (33.6%) had myocardial infarction (MI). The primary composite endpoint was major adverse cardiac and cerebrovascular event (MACCE) defined as death, MI, target vessel revascularization (TVR), and stroke assessed at one year. After propensity score analysis, there were no differences in MACCE (21.9% vs. 23.9%; HR 0.91, 95% CI 0.57–1.45, p = 0.681, respectively) nor in secondary endpoints of death, MI, TVR, target lesion revascularization (TLR) and stroke at one year in EPDs PCI group vs. no-EPDs PCI group. Similarly, there were no differences between groups in the study endpoints at 30 days follow-up. Conclusions: There were no clinical benefit for routine use of EPDs during SVG PCI in short and long-term follow-up. Further studies are warranted to explore the effect of individual types of EPDs on clinical outcomes.

show abstract

Saphenous graft atherosclerosis as assessed by optical coherence tomography data for stenotic and non-stenotic lesions from the OCTOPUS registry

Cited by 3 publications

References 30 publications

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

Multimodality intravascular imaging of bioresorbable vascular scaffolds implanted in vein grafts

The CHA2DS2-VASc Score as an Early Predictor of Graft Failure After Coronary Artery Bypass Surgery

Safety and Efficacy of Embolic Protection Devices in Saphenous Vein Graft Interventions: A Propensity Score Analysis—Multicenter SVG PCI PROTECTA Study

Contact Info

Product

Resources

About